Interestingly, HDAC inhibitors developed for cancer therapy do exert their activity in part via increasing the expression of BIM38,39 suggesting a potential molecular mechanism of how NCOR1 might repress BIM transcription. The gene discussed is HDAC9; the disease is cancer.